Drug intelligence / Profile preview

fluoxetine + magnesium

Development stage
Approved
Lead developer
Eli Lilly
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Fluoxetine + magnesium refers to the co-administration of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and magnesium, an essential mineral often used as a dietary supplement. Fluoxetine acts by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability and improving mood in conditions such as major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. Magnesium is involved in numerous physiological processes including nerve transmission and muscle contraction; it is commonly supplemented to prevent or treat magnesium deficiency. There is no evidence that "fluoxetine + magnesium" exists as a single fixed-dose combination product; rather, this refers to their concurrent use. Some clinical studies have explored whether adding magnesium supplementation to standard fluoxetine therapy may improve outcomes in depression. One small double-blind study found no significant difference between fluoxetine plus magnesium versus fluoxetine plus placebo on depression scores overall but suggested that certain patient characteristics (such as lower baseline depression scores or female gender) might increase the odds of remission when treatment was augmented with magnesium[5]. No major pharmacokinetic interactions are reported between these agents[2][6], though some sources note that therapeutic efficacy could be affected when combined[6]. Caution should always be exercised when combining supplements with prescription medications due to potential for unstudied interactions[4][7].

02

Targets

SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on fluoxetine + magnesium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine + magnesium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call